A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer

PURPOSE: Despite the efficacy of abiraterone, a CYP17A1 inhibitor, in metastatic castration-resistant prostate cancer (CRPC), nearly all patients develop resistance. The purpose of this phase II study was to evaluate mechanisms of resistance to more complete androgen synthesis inhibition with abirat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: McKay, Rana R., Werner, Lillian, Mostaghel, Elahe A., Lis, Rosina, Voznesensky, Olga, Zhang, Zhenwei, Marck, Brett T., Matsumoto, Alvin M., Domachevsky, Liran, Zukotynski, Katherine A., Bhasin, Manoj, Bubley, Glenn J., Montgomery, Bruce, Kantoff, Philip W., Balk, Steven P., Taplin, Mary-Ellen
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315609/
https://ncbi.nlm.nih.gov/pubmed/27683182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0987
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg